Low Dose Naltrexone (LDN): What the Research Shows for Autoimmune and Chronic Pain Conditions

Low Dose Naltrexone (LDN) is one of the most compelling examples of an evidence-based therapy that remains widely unknown among both patients and conventional practitioners. At doses far below those used for addiction treatment (1.5–4.5mg versus 50mg), naltrexone appears to modulate immune function and neuroinflammation in ways that benefit a surprising range of conditions — from Crohn's disease and multiple sclerosis to fibromyalgia and complex regional pain syndrome.

How LDN Works: The Mechanism

At low doses, naltrexone is thought to briefly block opioid receptors for just a few hours — a "rebound" effect that prompts the body to upregulate its own endorphin production. But the more clinically significant mechanism may involve microglial cells in the central nervous system. LDN appears to reduce the neuroinflammatory activity of microglia, which are implicated in chronic pain sensitization, autoimmune flares, and the fatigue associated with many chronic conditions.

What the Research Shows

The LDN Research Trust and independent researchers have published peer-reviewed studies on LDN across a growing range of conditions. The evidence base is strongest in Crohn's disease (pediatric and adult), fibromyalgia, and multiple sclerosis, but pilot data and case series exist for many others.

• Crohn's disease: Significant reduction in disease activity in pediatric and adult trials
• Fibromyalgia: Meaningful pain reduction and improved quality of life in randomized controlled trial
• Multiple sclerosis: Improved fatigue scores and quality of life measures
• Complex regional pain syndrome (CRPS): Case reports and series showing significant pain reduction
• Lupus and RA: Emerging observational data supporting immune modulation
• Long COVID: Growing anecdotal and early clinical evidence for symptom improvement

Who Is a Good Candidate for LDN?

LDN is generally considered safe and well-tolerated. It requires compounding (it is not available at standard pharmacies in low-dose form) and a physician's prescription. Important considerations include: patients on opioid medications cannot take LDN (the two drugs directly interfere), and thyroid function should be monitored in autoimmune thyroid patients as LDN can meaningfully affect hormone levels.

Our Approach at IMA

Dr. Fantasia has extensive experience with LDN protocols, has participated in LDN Research Trust collaborations, and is a recognized voice on LDN in integrative medicine. We use LDN as part of comprehensive protocols — alongside nutritional support, IV therapy where indicated, and lifestyle intervention — rather than as a standalone prescription. Most patients start at the lowest dose (1.5mg) and titrate slowly based on response.

LDN is not a miracle drug. But for a subset of patients — particularly those with autoimmune conditions, fibromyalgia, or treatment-resistant chronic pain — it can be genuinely transformative.